Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC
Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.
Marina Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the results of subgroup analyses of the phase 2 VISION trial (NCT02864992) in MET exon 14 (METex14) skipping mutation–positive non-small cell lung cancer (NSCLC).
The VISION trial evaluated the efficacy of tepotinib (Tepmetko) in patients with advanced or metastatic METex14-altered NSCLC. The results of a subgroup analysis of the study, which were presented during the 2021 ESMO Congress, demonstrated that patients older than the age of 75 years derived a robust response with durable clinical activity with tepotinib, Garassino says. This activity was similar to that observed in younger patients, Garassino adds.
Overall, the objective response rate was 52.2% in patients under the age of 75 years and 44.9% in patients at least 75 years old, Garassino says. Moreover, the confidence intervals overlapped, indicating tepotinib is an effective treatment option for elderly patients with METex14-altered NSCLC, Garassino concludes.
